Schedule a Call Back
PLI scheme for bulk drugs and medical devices receives 243 applications
Industry News- Dec 02,20
Production Linked Incentive (PLI) Scheme for bulk drugs and medical devices, which closed on 30 November 2020, received 215 and 28 applications from manufacturers of bulk drugs and medical devices respectively
New Delhi
Production Linked Incentive (PLI) Scheme for bulk drugs and medical devices, approved in March 2020 and notified in July 2020 with a total financial outlay of Rs 34.20 billion, has evoked a very positive response with 243 applications received from pharmaceutical and medical devices companies. ÂÂ
Under the PLI Scheme for bulk drugs, 215 applications were made by 83 pharmaceutical manufacturers. Similarly, 28 applications made by 23 manufacturers have been received under the PLI Scheme for medical devices. The closing date of applications was November 30, 2020. IFCI Ltd is the Project Management Agency (PMA) for implementation of both the schemes.
The appraisal process of the applications has commenced from December 1, 2020 and a maximum of 136 applications under the PLI scheme for bulk drugs and a maximum of 28 applications under the PLI scheme for medical devices will be approved. The time duration for giving approval to the applicants is 90 days under the PLI scheme for bulk drugs and 60 days under the PLI scheme for medical devices. However, best efforts will be done by the PMA and the Department of Pharmaceuticals to give early approvals to the participants under the scheme.
Looking at the increasing imperative of drug security, support to domestic production capability in bulk drugs would ensure higher resilience of the Indian pharmaceutical industry to external shocks. The PLI scheme for medical devices will help meet the objective of product diversification and production of innovative and high value medical devices in India. These initiatives have the potential to contribute significantly to achieving higher objective of affordable healthcare in the country and globally on a sustained basis.
The PLI Schemes for bulk drugs and medical devices - along with electronics manufacturing industry - was approved by the Government on March 20, 2020. For bulk drugs & medical devices, the initial guidelines for implementation of both the schemes which were initially issued on July 27, 2020 were amended based on the feedback received from the industry. These revised guidelines were issued on October 29, 2020. Both the schemes have shown a very encouraging response from the pharmaceutical as well as the medical device industry.
In October 2020, Ministry of Electronics and Information and Technology (MeitY) approved 16 eligible applicants under the PLI Scheme for electronics manufacturing.ÂÂ
In November 2020, as part of Aatmanirbhar Bharat 3.0 initiative, the Government of India has extended the PLI Scheme to 10 new sectors with additional financial outlay of Rs 1460 billion over a 5-year period to enhance India’s manufacturing capabilities and enhancing exports. The new sectors that are included for the scheme are advance chemistry cell (ACC) battery, electronic/technology products, automobiles & auto components, pharmaceutical drugs, telecom & networking products, textile products (man-made fibres and technical textiles), food products, high efficiency solar PV modules, white goods (ACs & LED), and speciality steel.
The Indian pharmaceutical industry is the third largest in the world by volume and 14th largest in terms of value. It contributes 3.5 per cent of the total drugs and medicines exported globally. India possesses the complete ecosystem for development and manufacturing of pharmaceuticals and a robust ecosystem of allied industries. Under PLI scheme 2.0, Rs 150 billion has been allocated for pharmaceutical industry to incentivise the global and domestic players to engage in high value production.
Advance Chemistry Cell
Project Management Agency
PLI scheme
bulk drugs
medical devices
Production Linked Incentive
pharmaceuticals
electronics
Aatmanirbhar Bharat
Department of Pharmaceuticals
Related Stories
Auto & Auto Components
India’s PV and CV sales surge as EVs, infrastructure drive growth
India’s passenger and commercial vehicle markets are expanding on policy support, infrastructure growth, rising incomes, exports and faster EV adoption.
Read moreAuto & Auto Components
India’s EV Opportunity Moves Beyond the Showroom
With EV sales rising and component demand set to multiply, India’s next mobility phase will depend on localisation, technology ownership, policy execution and the strength of domestic manufacturin..
Read moreSmart Manufacturing
L&T EPS to invest Rs 50 bn in electronics push, targets EV mobility for growth
L&T Electronic Products & Systems (LTEPS) is accelerating its mobility ambitions with indigenous EV motors, motor control units, ADAS and connected vehicle solutions as part of its Rs 50 billion ele..
Read moreRelated Products
Programmable Controllers - Pcd-33a Series
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Pro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.
Gasket Graphite Powder
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Arihant Packing & Gasket Company offers a wide range of gasket graphite powder.
Asahi Kasei expands 3D printing filament sales in North America
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more
latest News
Subscribe to iNoW
For Industry News on WhatsApp, Give a Miss Call on: +91 84228 74016
